Application and efficacy evaluation of durvalumab (durvalumab) in immunotherapy

Durvalumab (Durvalumab) is an immune checkpoint inhibitor and a humanized anti-PD-L1 (programmed death ligand 1) monoclonal antibody. It restores the body's immune system's ability to recognize and attack tumor cells by blocking the binding of PD-L1 and its receptors PD-1 and B7.1, and significantly enhances the anti-tumor immune response. In recent years, durvalumab has shown good efficacy and safety in the immunotherapy of various cancers and has become one of the important drugs in the field of tumor immunotherapy.

1. The mechanism of action of durvalumab and the principle of immunotherapy

Tumor cells inhibit the activity of T cells by expressing PD-L1 protein, making the immune system unable to effectively identify and eliminate cancer cells. As an inhibitor of PD-L1, durvalumab can block this "immune escape" pathway, relieve the inhibition of T cells, and promote the restoration of the killing function of immune cells. This mechanism makes durvalumab play a key role in enhancing the body's own anti-tumor immunity, which is especially suitable for patients with tumors that express positive PD-L1 expression.

2. Main clinical indications of durvalumab

Currently, durvalumab has been approved for the treatment of a variety of malignant tumors, including but not limited to:

Non-small cell lung cancer (NSCLC): Especially locally advanced and unresectable III non-small cell lung cancer, as a maintenance treatment after radiotherapy and chemotherapy, it can significantly extend the progression-free survival (PFS) and overall survival (OS).

Small cell lung cancer (SCLC): In the treatment of locally advanced small cell lung cancer, durvalumab combined with chemotherapy has shown improved efficacy and prolonged patient survival.

Urothelial carcinoma: As a maintenance therapy after platinum-based chemotherapy, durvalumab has shown good efficacy in delaying disease progression.

In addition, durvalumab is undergoing clinical trials in multiple other cancer types and has broad potential.

3. Efficacy evaluation and clinical research results

A large amount of clinical trial data confirms the important role of durvalumab in immunotherapy. For example, in the PACIFIC trial, patients with locally advanced stage III non-small cell lung cancer received durvalumab maintenance therapy after completing radiotherapy and chemotherapy. Compared with the placebo group, the progression-free survival was significantly longer, and the overall survival of some patients was also significantly improved, showing good clinical benefit.

In addition, the use of durvalumab in urothelial cancer has also been approved by the FDA. Studies have shown that the drug can effectively prolong disease remission and improve patients' quality of life. The evaluation of efficacy is mainly based on imaging examinations (such as CT, MRI), biomarker detection and patient clinical performance. The reduction of tumor burden and the relief of symptoms are key indicators.

4. Safety and Tolerability

The immune-related side effects of durvalumab mainly include rash, abnormal liver function, pneumonia, thyroid dysfunction, etc. Most of these side effects are controllable, and through early monitoring and timely treatment, the risk of serious adverse reactions can be effectively reduced. Compared with traditional chemotherapy, durvalumab is better tolerated and the patient's quality of life is greatly improved.

5. Future Outlook

With the continuous development of the immunotherapy field, durvalumab's application scope and combination therapy continue to expand. For example, research on the combination with other immune checkpoint inhibitors, targeted drugs and chemotherapy is in full swing, aiming to further improve the efficacy and prolong patient survival. In addition, finding accurate biomarkers and selecting patient groups suitable for treatment have also become the focus of current research.

In summary, durvalumab, as a PD-L1 inhibitor, plays an important role in the immunotherapy of various tumors and has significant clinical efficacy and good safety. In the future, with the advancement of more clinical studies, durvalumab is expected to play greater value in the field of tumor treatment and bring new hope to patients.

Reference materials:https://www.imfinzi.com/